Detection of anti‐domain I antibodies by chemiluminescence enables the identification of high‐risk antiphospholipid syndrome patients: A multicenter multiplatform study
| Autor: | Dongmei Yin, Katrien Devreese, Walid Chayoua, Gary W. Moore, Bas de Laat, Jacek Musiał, Hilde Kelchtermans, Jean-Christophe Gris, Stéphane Zuily, Philip G. de Groot |
|---|---|
| Přispěvatelé: | Cardiovascular Research Institute Maastricht (CARIM), Maastricht University [Maastricht], Synapse Research Institute, Guy's and St Thomas' Hospitals, Centre Hospitalier Universitaire de Nîmes (CHU Nîmes), Sechenov First Moscow State Medical University, Défaillance Cardiovasculaire Aiguë et Chronique (DCAC), Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lorraine (UL), Uniwersytet Jagielloński w Krakowie = Jagiellonian University (UJ), Ghent University Hospital, Biochemie, RS: Carim - B01 Blood proteins & engineering |
| Rok vydání: | 2020 |
| Předmět: |
Male
Luminescence MESH: Pregnancy Complications Cardiovascular multicenter 030204 cardiovascular system & hematology Gastroenterology Epitope Epitopes MESH: Pregnancy 0302 clinical medicine Pregnancy Odds Ratio beta 2-glycoprotein I MESH: Aged MESH: Immunoglobulin G BETA(2)-GLYCOPROTEIN I Lupus anticoagulant MESH: Middle Aged Hematology MESH: Beta 2-Glycoprotein I medicine.diagnostic_test biology MESH: Luminescence [SDV.MHEP.HEM]Life Sciences [q-bio]/Human health and pathology/Hematology ASSOCIATION Middle Aged pregnancy morbidity 3. Good health MESH: Reproducibility of Results Lupus Coagulation Inhibitor MESH: Protein Domains [SDV.IMM]Life Sciences [q-bio]/Immunology BETA-2-GLYCOPROTEIN-I Female Antibody Adult medicine.medical_specialty MESH: Epitopes MESH: Lupus Coagulation Inhibitor Pregnancy Complications Cardiovascular DIAGNOSIS AUTOIMMUNE-DISEASES IMMUNOASSAY 03 medical and health sciences Protein Domains [SDV.MHEP.CSC]Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular system Antiphospholipid syndrome Internal medicine MESH: Antiphospholipid Syndrome medicine Humans Beta 2-Glycoprotein I Aged MESH: Humans β2-glycoprotein I business.industry MESH: Antibodies Anticardiolipin IGG ANTIBODIES Autoantibody Reproducibility of Results MESH: Adult medicine.disease MESH: Male MESH: Odds Ratio THROMBOSIS domain I Antibodies Anticardiolipin Immunoglobulin G Immunoassay biology.protein AUTOANTIBODIES business MESH: Female antiphospholipid syndrome PATHOGENICITY |
| Zdroj: | Journal of Thrombosis and Haemostasis Journal of Thrombosis and Haemostasis, Wiley, 2020, 18 (2), pp.463-478. ⟨10.1111/jth.14682⟩ Journal of Thrombosis and Haemostasis, 18(2), 463-478. Wiley |
| ISSN: | 1538-7836 1538-7933 |
| DOI: | 10.1111/jth.14682 |
| Popis: | Background Classification of the antiphospholipid syndrome (APS) relies predominantly on detecting antiphospholipid antibodies (aPLs). Antibodies against a domain I (DI) epitope of anti-beta 2glycoprotein I (beta 2GPI) proved to be pathogenic, but are not included in the current classification criteria. Objectives Investigate the clinical value of detecting anti-DI IgG in APS. Patients/Methods From eight European centers 1005 patients were enrolled. Anti-cardiolipin (CL) and anti-beta 2GPI were detected by four commercially available solid phase assays; anti-DI IgG by the QUANTA Flash (R) beta 2GPI domain I assay. Results Odds ratios (ORs) of anti-DI IgG for thrombosis and pregnancy morbidity proved to be higher than those of the conventional assays. Upon restriction to patients positive for anti-beta 2GPI IgG, anti-DI IgG positivity still resulted in significant ORs. When anti-DI IgG was added to the criteria aPLs or used as a substitute for anti-beta 2GPI IgG/anti-CL IgG, ORs for clinical symptoms hardly improved. Upon removing anti-DI positive patients, lupus anticoagulant remained significantly correlated with clinical complications. Anti-DI IgG are mainly present in high-risk triple positive patients, showing higher levels. Combined anti-DI and triple positivity confers a higher risk for clinical symptoms compared to only triple positivity. Conclusions Detection of anti-DI IgG resulted in higher ORs for clinical manifestations than the current APS classification criteria. Regardless of the platform used to detect anti-beta 2GPI/anti-CL, addition of anti-DI IgG measured by QUANTA Flash (R) did not improve the clinical associations, possibly due to reduced exposure of the pathogenic epitope of DI. Our results demonstrate that anti-DI IgG potentially helps in identifying high-risk patients. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text